LCD L36117: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — CGS
Policy LCD-L36117 · Hematology
New genetic testing LCD affects billing for myeloproliferative disease.
Code intelligence
D47.1 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D47.1.
Elevated code riskView ICD-10 detail
Signal breakdown
10 shown · 10 total in platform
Risk: Elevated
0
Critical
0%
6
High
60%
4
Routine
40%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36044: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Palmetto GBA
Policy LCD-L36044 · Hematology
New guidelines impact billing for genetic tests in myeloproliferative disease.
LCD L36180: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian
Policy LCD-L36180 · Hematology
New genetic testing guidelines announced by Noridian.
LCD L36186: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian
Policy LCD-L36186 · Hematology
Impact on genetic testing billing for myeloproliferative diseases.
LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39927 · Hematology
New LCD for myeloproliferative neoplasm testing impacts billing.
LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
Policy LCD-L40000 · Hematology
New LCD impacts billing for myeloproliferative neoplasms testing.
LCD L37622: MDS FISH — Noridian
Policy LCD-L37622 · Clinical Laboratory
Understanding MDS FISH LCD billing is crucial for labs.
Proposed LCD DL39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-DL39927 · Oncology
Impact of LCD on billing for myeloproliferative neoplasms testing.
Proposed LCD DL40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
Policy LCD-DL40000 · Hematology
Impact on billing for tests on myeloproliferative neoplasms.
Proposed LCD DL39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-DL39923 · Hematology
New LCD may affect reimbursement for myeloproliferative tests.
Audit documentation
Building an audit file that includes D47.1?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription